FRESENIUS SE: Berenberg reaffirms its Buy rating

Berenberg analyst Tom Jones maintains his Buy rating on the stock. The target price continues to be set at EUR 59.50.
https://www.marketscreener.com/FRESENIUS-SE-CO-KGAA-436083/news/FRESENIUS-SE-Berenberg-reaffirms-its-Buy-rating-30301344/

ROCHE HOLDINGS AG: Barclays reiterates its Buy rating

Barclays and its analyst Emmanuel Papadakis still consider the stock as a Buy opportunity.. The target price is revised downwards from CHF 375 to CHF 385.
https://www.marketscreener.com/ROCHE-HOLDING-AG-9364975/news/ROCHE-HOLDINGS-AG-Barclays-reiterates-its-Buy-rating-30301451/

Neurocrine Bio suspends enrollment in key study amid COVID-19

Neurocrine Biosciences (NASDAQ:NBIX) provides an update on its business operations during the COVID-19 pandemic.

The company continues to perform all activities necessary to initiate a global registrational study of crinecerfont in adult congenital adrenal hyperplasia (CAH) patients in mid-2020.

The commercial launch of opicapone is expected to be delayed until later this year.

Neurocrine is temporarily pausing enrollment of new patients in the Phase III study of valbenazine for chorea in Huntington disease, the RESTORE-1 registrational study for NBIb-1817 in Parkinson’s disease and the Phase IIa pediatric study of crinecerfont in CAH.

The company plans to have on-going studies in three registrational programs and five mid-stage programs by the end of 2020.

NBIX has donated supplies to San Diego area hospitals in response to COVID-19.

https://seekingalpha.com/news/3558168-neurocrine-bio-suspends-enrollment-in-key-study-amid-covidminus-19

Google offers location data for coronavirus lockdowns

Big Brother or necessary surveillance? You decide.

In an effort to assist in “unprecedented times,” Google (GOOG, GOOGL) is helping public health officials use its vast storage of data to track people’s movements due to the coronavirus pandemic.

The “mobility reports” go down to the county level to see if locals are abiding by social-distancing measures, but will use anonymized historical data, with a lag of two or three days.

Google is also reportedly exploring individual location tracking with a White House task force, as well as running a handful of testing sites in Northern California in a private-public partnership with the government.

https://seekingalpha.com/news/3558091-google-offers-location-data-for-coronavirus-lockdowns

Zentalis Pharma prices IPO at $18

Zentalis Pharmaceuticals (ZNTL) has priced its initial public offering (IPO) of 9.18M common shares at $18.00 per share yielding total proceeds of ~$165.2M.

Underwriters’ over-allotment is an additional 1,377,000 shares.

Closing date is April 7.

Trading kicks off today.

https://seekingalpha.com/news/3558109-zentalis-pharma-prices-ipo-18

Incyte to test Jakafi in COVID-19 patients

Incyte (NASDAQ:INCY) is working with the FDA to initiate a Phase 3 clinical trial, RUXCOVID, to evaluate the efficacy and safety of ruxolitinib (Jakafi) plus standard-of-care (SoC), compared to SoC therapy alone, in patients with COVID-19 associated cytokine storm.

Additionally, the company intends to launch a separate Expanded Access Program in the U.S. to allow eligible patients with COVID-19 associated cytokine storm to receive ruxolitinib.

https://seekingalpha.com/news/3558122-incyte-to-test-jakafi-in-covidminus-19-patients

FDA OKs emergency use of Becton, Dickinson/BioGX coronavirus test

The FDA has granted Emergency Use Authorization for BioGX’s molecular diagnostic test the detects the presence of SARS-CoV-2, the virus causing COVID-19.

The test is performed on Becton, Dickinson and Company’s (NYSE:BDX) automated BD MAX System that can process 24 samples at a time with results generated in under three hours.

https://seekingalpha.com/news/3558124-fda-oks-emergency-use-of-becton-dickinson-biogx-coronavirus-test